T he emergence and spread of Mycobacterium tuberculosis (Mtb) resistant to multiple antituberculosis drugs is of global concern. Programmatically incurable tuberculosis (TB), where effective treatment regimens cannot be provided owing to resistance to the available drugs, is a growing problem 
*
To characterize the genetic determinants of resistance to antituberculosis drugs, we performed a genome-wide association study (GWAS) of 6,465 Mycobacterium tuberculosis clinical isolates from more than 30 countries. A GWAS approach within a mixed-regression framework was followed by a phylogenetics-based test for independent mutations. In addition to mutations in established and recently described resistance-associated genes, novel mutations were discovered for resistance to cycloserine, ethionamide and para-aminosalicylic acid. The capacity to detect mutations associated with resistance to ethionamide, pyrazinamide, capreomycin, cycloserine and para-aminosalicylic acid was enhanced by inclusion of insertions and deletions. Odds ratios for mutations within candidate genes were found to reflect levels of resistance. New epistatic relationships between candidate drug-resistance-associated genes were identified. Findings also suggest the involvement of efflux pumps (drrA and Rv2688c) in the emergence of resistance. This study will inform the design of new diagnostic tests and expedite the investigation of resistance and compensatory epistatic mechanisms.
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(MDR-TB), and further resistance to the fluoroquinolones and any of the injectable drugs (amikacin, kanamycin or capreomycin) used to treat MDR-TB is termed extensively drug-resistant tuberculosis (XDR-TB). Treatment for patients with drug-resistant tuberculosis is prolonged and expensive, and outcomes are poor 2 . The drugs used are toxic and poorly tolerated, and adverse events are common and may be severe and irreversible 3 . Inadequate treatment also risks amplification of resistance to further drugs and may prolong opportunities for transmission 4 . Mtb has a clonal genome (size of 4.4 Mb) with a low mutation rate and no evidence of between-strain recombination or horizontal gene transfer 5 . The Mtb complex comprises seven lineages, of which four are predominant in humans: lineage 1, Indo-Oceanic (for example, East African-Indian (EAI) spoligotype families); lineage 2, East Asian (for example, W/Beijing spoligotype families); lineage 3, East African-Indian (for example, Central Asian strain (e.g., CAS-DELHI) spoligotype families); and lineage 4, Euro-American (for example, Latin American-Mediterranean (LAM), Haarlem and the 'ill-defined' T spoligotype families) 5 . Resistance in Mtb is mainly conferred by nucleotide variations (SNPs and indels) in genes encoding drug targets or drug-converting enzymes. Changes in efflux pump regulation may have an impact on the emergence of resistance 6 , and putative compensatory mechanisms to overcome fitness impairment coincidental with the acquisition of resistance have been described for some drugs 7 . Detection of resistance-conferring mutations offers a means of rapidly identifying resistance to antituberculosis drugs 8 but, with the exception of rifampicin, current molecular tests for resistance lack high levels of sensitivity 8 . To improve knowledge of genetic determinants of drug resistance, we undertook whole-genome analysis of a large collection of clinical isolates (n = 6,465) from more than 30 geographic locations, representing the four major Mtb lineages ( Fig. 1 and Supplementary Table 1) . We adopted a GWAS approach to identify nucleotide variation and loci underlying drug resistance as successfully applied in Mtb [9] [10] [11] and other bacteria 12, 13 . A total of 14 drugs with available phenotypic data on drug susceptibility testing were investigated (Supplementary Table 2 ). Phenotypic drug susceptibility data were not available for each of the 14 drugs for every isolate, and sample sizes ranged from over 6,000 for the most commonly tested first-line drugs (isoniazid and rifampicin) to 255 and 248 for para-aminosalicylic acid and cycloserine, respectively, which are used to treat patients with XDR-TB. Here we present findings from the most comprehensive study yet undertaken of the genetic determinants of resistance to antituberculosis drugs, or the Mtb resistome.
Results
Genetic diversity and drug resistance. High-quality genomewide SNPs (102,160), indels (11, 122 ) and large deletions (284) were identified across all samples (n = 6,465). Most SNPs (93.1%) had rare minor alleles (allele frequency < 1%) ( Supplementary  Fig. 1 ). Similarly, small indels were rare (96.6% had frequency < 1%) and ranged in size from 1 to 45 bp. A phylogenetic tree and principal-component analysis constructed using all genomewide SNPs showed the expected clustering by lineage ( Fig. 2 and Supplementary Fig. 2 ).
Phenotypic analysis of susceptibility to antituberculosis drugs found that 31.2% of isolates were resistant to at least one drug, with 15.1% categorized as MDR-TB and 4.3% categorized as XDR-TB (Fig. 2 and Supplementary Table 2 ). Fourteen drugs were included in the genome-wide analysis: isoniazid (INH), rifampicin (RIF), ethionamide (ETH), pyrazinamide (PZA), ethambutol (EMB), streptomycin (STM), amikacin (AMK), capreomycin (CAP), kanamycin (KAN), ciprofloxacin (CIP), ofloxacin (OFL), moxifloxacin (MOX), cycloserine (CYS) and para-aminosalicylic acid (PAS). Drug family groups including the second-line injectable drugs (SLIDs: AMK, KAN and CAP) and fluoroquinolones (FLQs: CIP, OFL and MOX) were also analyzed. Insufficient phenotypic data were available for Table 1 for a detailed description of each dataset. Inner pie charts show the proportion of each of the main four lineages, and the outer charts summarize the drug resistance phenotypes. "Drug-resistant" refers to resistant strains not classified as MDR-TB or XDR-TB.
inclusion of the new and repurposed drugs bedaquiline, delamanid and linezolid. To identify loci associated with drug resistance, complementary methods were applied to mutations and aggregated nonsynonymous mutations: a tree-based 'PhyC' test for convergent evolution to detect homoplastic variants 9 and a GWAS approach within a mixed-regression framework (Methods). Unless stated otherwise, all analysis used the complete dataset. First, we considered MDR-TB and XDR-TB phenotypes (Table 1) and then individual-drug GWAS and evolutionary results (Table 2) .
GWAS and PhyC tests for MDR-TB and XDR-TB.
The gene-based GWAS of MDR-TB versus susceptible isolates identified rpoB (RIF), the Rv1482c-fabG1 operon (INH, ETH), inhA (INH, ETH), katG (INH) and oxyR´-ahpC (compensatory mechanism for INH). The katG mutations at codon 315 (encoding p.Ser315Thr, p.Ser315Asn, p.Ser315Arg) were all statistically significant and collectively were the most frequent mutations (75.2%) across all the resistance-associated loci identified, consistent with a recent study 14 and highlighting their pivotal role in the emergence of INH resistance and MDR-TB. The katG mutation encoding p.Ser315Thr is thought to emerge before mutations associated with RIF resistance and, therefore, from an evolutionary standpoint, to precede the emergence of MDR-TB 14, 15 . However, our analysis highlighted that Rv1482c-fabG1 and inhA mutations, in the absence of katG p.Ser315Thr, can emerge before MDR-TB, as previously shown in two phylogenetically independent clades in Lisbon 16, 17 . The other frequent MDR-TB-associated mutations in our study included rpoB p.Ser450Leu (RIF, 64.2%), embB p.Met306Leu, p.Met306Val and p.Met306Ile (EMB, 49.1%), and rpsL p.Lys43Arg (STM, 42.2%) (Supplementary Table 3) , and the prevalence correlated with historical treatment practice and emergence of resistance. There were corresponding signals of INH-RIF co-resistance with resistance for other first-line drugs, and gene-based association signals were detected for gid (STM) and rpsL (STM) and a SNP-based association signal was detected for the embC-embA intergenic region (EMB). SNP-based PhyC analysis detected the above loci but in addition identified folC (PAS), the pncA-Rv2044c intergenic region (PZA) and the whiB6-Rv3863 intergenic region (putative STM or ETH).
The gene-based GWAS of XDR-TB versus MDR-TB identified mutations in gyrA (FLQ), rrs (aminoglycosides), the embC-embA intergenic region and ubiA (EMB). The PhyC test additionally revealed eis-Rv2417c (KAN), gyrB (FLQ), rrs (aminoglycosides), folC (PAS), alr (CYS) and gid (STM) SNPs and a new mutation in the thyX-hsdS.1 intergenic region (c.-9A> T; PAS) 18, 19 . In addition to the loci identified above, the gene-based GWAS comparing XDR-TB to susceptible groups identified rpoC (a compensatory mechanism for RIF resistance), ethA (ETH), eis-Rv2417c (KAN) and PPE52-nuoA (a new intergenic region; c.-314G> T). The PhyC test additionally detected SNPs in gyrB (FLQ; encoding p.Asp461Asn, p.Asp641His, p.Thr500Asn, p.Thr500Ile and p.Ala504Val) and supported the SNP finding in the thyX-hsdS.1 intergenic region (PAS; c.-9A> T), as well as identified a previously unreported ubiA SNP association (EMB; p.Met180Val).
The drrA mutation encoding p.Arg262Gly was significantly associated with XDR-TB as compared to susceptible bacteria (mutation frequency = 18% versus 0%, P = 1.5 × 10
−8
). We hypothesize that drrA may be involved in export of drugs across the membrane on the basis of its strong association with XDR-TB in our study and its functional annotation as a probable transporter of antibiotics across the membrane (TubercuList; see URLs). This hypothesis is in accordance with the finding that rpoB mutations in Mtb may trigger compensatory transcriptional changes in genes involved in secondary metabolism, in particular, in the biosynthesis and export of phthiocerol dimycocerosate (PDIM), increasing expression and activity. As a consequence, these strains became more virulent and multidrug resistant, increasing their fitness through increased efflux activity and lipid metabolism 20, 21 . Similarly, a mutation in the Rv1144-mmpL13a intergenic region (c.-102C> A) was highly associated with XDR-TB versus susceptibility (mutation frequency = 17% versus 0%, P = 1.5 × 10
−7
). This mutation sits in the promoter of the operon containing mmpL13a and mmpL13b, which encode transmembrane transport proteins, and thus could influence expression of the encoded proteins 6 .
Lineage-specific and compensatory mechanisms. We conducted GWAS stratified by lineage to identify lineage-specific loci associated with drug resistance. Most associations were present in more than one lineage. The largest number of lineage-specific mutations associated with drug resistance were found in lineage 4, which was the largest collection investigated and contained more genetically diverse clones 5 , implying that geographically restricted mutations are being captured (Supplementary Table 4 ). A previously unreported putative compensatory locus was identified for PZA (pncB1) through analysis of lineage 1, and this locus reached borderline significance for lineage 3.
We applied a systematic approach to identify epistatic interactions between GWAS loci (from Table 2 ) and explored known compensatory effects using a test of non-random association to detect the frequent co-occurrence of mutations in pairs of loci (Fisher's exact test, P-value cutoff < 1 × 10 Table 5 ). Deep phylogenetic mutations were removed to increase robustness. This approach proved to be successful at identifying well-known compensatory relationships between the rpoB and rpoC loci (RIF) 7 , the rpoB and rpoA loci (RIF) 22 , and the katG and oxyR´-ahpC loci (INH) 23 . We captured the frequent co-occurrence of embB and ubiA mutations, which together are known to lead to high levels of EMB resistance 24 , and these mutations are therefore unlikely to represent a compensatory mechanism. New epistatic relationships included pncA with pncB2 (PZA) and thyA with thyX-hsdS.1 (PAS). The pncB2 epistatic effect with pncA appeared to be specific to lineage 4 (Supplementary Table 6 ). The other nicotinamide cofactor, pncB1, had weaker evidence of an epistatic relationship with pncA in lineage 1 (P = 0.0016) (Supplementary Table 6 ). Similarly, there was marginal evidence for an effect of pyrG (lineage 4, P = 0.00016) 25 and Rv0565c (lineage 2, P = 0.00027) with ethA (ETH) 26 (Supplementary Table 6 ). Follow-up investigations will need to determine whether mutations in these loci have an impact on minimal inhibitory concentration (MIC) values or function as compensatory mechanisms.
Overall, the GWAS approach was effective at detecting known drug resistance determinants and epistatic (gene-gene) relationships, and it identified new ones that warrant functional validation in future studies.
GWAS and PhyC tests for individual drugs.
As resistance-conferring loci for individual drugs, especially second-line treatments, may be masked by an analysis of the composite MDR-TB and XDR-TB outcomes, we repeated the GWAS, PhyC test and epistatic analysis for the 14 individual drugs considered.
Rifampicin, isoniazid and ethionamide. The rpoB locus showed the strongest association with RIF resistance, but the compensatory effects of rpoC and rpoA were also evident through homoplastic SNP analysis. As previously reported, nonsynonymous SNPs in rpoC (272 identified) were spread across the whole gene 27 . Altered or diminished activity of the catalase-peroxidase enzyme KatG is the most frequent mechanism of INH resistance 28 , and, as expected, the katG gene ranked first in the GWAS for this drug. Mutations in proposed INH drug targets kasA and kasB previously included in some drug resistance databases did not reach statistical significance in our study 29 , suggesting an odds ratio below our detection level of 1.4 (with 99% confidence of detection, 90% statistical power). Both inhA, encoding the molecular target of INH 30 , and the Rv1482c-fabG1 intergenic region harboring its promoter, showed strong associations with INH and ETH, with greater effects in the former. In addition, mutations associated with the oxyR´-ahpC intergenic region (20 detected) were found in the presence of katG polymorphisms (28), supporting its role as a compensatory mechanism in INH-resistant strains. For ETH, the ethA locus, encoding the drug-metabolizing enzyme, was found to be associated with resistance as described previously 31 . A total of 153 nonsynonymous mutations were identified in ethA, scattered throughout the gene and mostly affecting codons different from those already described 8 .
Ethambutol. Mutations in the embCAB operon, which encodes enzymes involved in the biosynthesis of arabinan components of the mycobacterial cell wall, are mostly responsible for EMB resistance, but are not fully penetrant for resistance 32 . The embB locus and the embC-embA intergenic region had the strongest associations. Rv3806c (ubiA), described to contribute to high levels of EMB resistance in vitro 17 , was also significantly associated in our analysis, also demonstrating a role in clinical samples across all four lineages. Two novel loci were identified: Rv2820c, thought to enhance mycobacterial virulence ex vivo and in vivo, and Rv3300c, encoding a conserved protein of unknown function (TubercuList; see URLs).
Pyrazinamide. The pncA locus was the highest ranked association with PZA resistance in the GWAS and was a target of independent mutation, consistent with its established role 33 . Additionally, many low-frequency SNPs were reported that were not used in the association analysis and could potentially confer resistance (Supplementary Data 1). Other proposed PZA targets, namely rpsA 34 and panD 35 , did not reach statistical significance in the GWAS and were not targets of independent mutation among PZA-resistant strains in our collection.
Streptomycin. The rpsL, rrs and gid loci, all known to be involved in STM resistance 18 , were identified by GWAS. Mutations in rpsL are known to lead to intermediate to high levels of STM resistance 36 ; accordingly, we observed high odds ratios indicative of high penetrance in association signals in this locus (Fig. 3a) . In contrast, candidate rrs and gid gene polymorphisms showed weaker overall signals (lower odds ratio) in the GWAS, which concurs with existing evidence that gid and rrs mutations confer lower levels of resistance 36 (differences in odds ratios: rpsL versus rrs or gid Wilcoxon P = 0.03; rpsL versus gid Wilcoxon P = 0.04).
Fluoroquinolones and second-line injectables. The gene-and SNPbased GWAS analyses identified the gyrA locus, which encodes the molecular target of FLQ 37 , as the strongest association signal. In addition to homoplastic mutations in gyrA, evidence of independent mutation was detected in gyrB 38 . The Rv2688c mutation encoding p.Cys213Arg was associated with MOX and FLQ resistance, but did not reach statistical significance for OFL. The antibiotic transport ATP-binding protein encoded by Rv2688c is a known FLQ efflux pump 39 . As expected, the strongest gene-and SNP-based association signals for resistance across AMK, KAN and CAP were with the aminoglycoside (SLID) target gene rrs 18 . Association was observed with mutations in the eis promoter known to result in low levels of KAN resistance but not in co-resistance with other aminoglycosides 40 . Although the eis promoter mutations had a lower median odds ratio than rrs mutations, potentially providing evidence that rrs mutations confer higher levels of KAN resistance 40 , this was not statistically significant owing to small sample size (differences in odds ratios Wilcoxon P = 0.24) (Fig. 3a) .
d-Cycloserine. CYS inhibits the Alr enzyme, responsible for the conversion of l-alanine into d-alanine, by competing with l-alanine for the active site. Resistance to CYS results from mutations in the alr coding region 41 . In our study, alr was significantly associated with CYS resistance (Table 2 ), in line with recent evidence showing that clinical strains with alr mutations exhibit increased resistance to CYS 11 , and harbored multiple homoplastic mutations, including those encoding p.Phe4Leu, p.Lys113Arg and p.Met343Thr. In a previous study, the mutation encoding p.Met343Thr was detected in an XDR-TB strain that had been exposed to CYS treatment, was predicted to alter the protein structure of Alr and was therefore hypothesized to be involved in CYS resistance 42 . To further understand the functional impact of the mutations found in alr, we modeled the effect of these variants using the available crystal structure for the protein (PDB 1XFC; Supplementary Fig. 3 ). Variants in Alr were found to differ in their proximity to the CYS-binding site and their effect on protein stability and ligand binding (Supplementary Table 7 ). The p.Met343Thr substitution (found in 12 susceptible and 2 resistant isolates) was predicted to have a more drastic effect on protein structure than p.Lys113Arg, corresponding to the most frequent mutation among CYS-resistant isolates (in 7 susceptible and 23 resistant isolates). There appears to be a balance between the fitness costs associated with mutations and mutation frequency (Supplementary Table 7 ). The mutation encoding p.Met343Thr appeared independently throughout the phylogenetic tree but did not reach statistical significance for association with drug resistance (XDR-TB or CYS), implying that selection may be acting on this mutation but drug resistance may not be the driving factor. para-Aminosalicylic acid. PAS is a prodrug that is converted into its active form by ThyA-a thymidylate synthase, which is encoded by a gene essential for Mtb survival. The candidate drug resistance loci are involved in folate metabolism and biosynthesis of thymidine ) for each gene are arranged by increasing median value (as represented by the horizontal line in each box) to show relative effects on resistance. Mutations known to confer low, intermediate or high levels of resistance (Methods) are represented by points colored blue, yellow and red, respectively, and point size is proportional to mutation frequency. Overall, higher levels of resistance are reflected by higher odds ratios; one exception is for rrs and CAP, where the c.1484G> C or c.1484G> T mutation (high-level resistance) has a lower odds ratio than c.1401A> G (intermediate level) owing to its low frequency. A similar effect is seen for the same c.1484G> C and c.1484G> T mutations in KAN resistance. b, The distribution of log odds ratios (P < 1 × 10
) for mutations within unknown (n = 167) or known loci conferring low (n = 17) (blue), intermediate (n = 16) (yellow) or high (n = 11) (red) levels of resistance. c, The distribution of log odds ratios for known (n = 171) and novel (n = 40) drug-resistance-conferring mutations (P < 1 × 10
−5
). All box plots consist of boxes (median and interquartile range) and whiskers that extend to the most extreme data points that were no more than 1.5 times the interquartile range from the box.
nucleotides (thyA, dfrA, folC, folP1, folP2 and thyX) 
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. Of these, thyA and thyX-hsdS.1 (directly upstream of thyX) were found to be associated with PAS drug resistance in both gene-and SNP-based GWAS analyses. Notably, it has been shown that the c.-16G> A SNP found in our study increases thyX expression by 18-fold relative to the wild-type promoter, although no link with PAS resistance was made 18 . Of the three PAS-resistant strains with the c.-16G> A mutation in the thyX promoter, two also had a thyA mutation (p.Pro145Leu and p.His207Arg), further supporting the idea that upregulation of thyX is involved in resistance to PAS 26 or has a compensatory role. The c.-16G> A thyX mutation is a homoplastic mutation and is therefore more likely to be compensatory.
Overall, the log-transformed odds ratios for the association of mutations with known levels of resistance followed an increasing trend from low to intermediate to high (Fig. 3b ; log odds ratios: linear regression trend P = 1.5 × 10 ). This analysis demonstrates the potential utility of odds ratios and their statistical significance as an indicator of the impact of a mutation and its propensity to cause low-, intermediate-or high-level resistance. Further, the odds ratios for the novel findings were marginally lower than those for known ones (Wilcoxon test P = 8.3 × 10 -5 ), reflecting the ability of the GWAS to discover effect sizes of lower magnitude (Fig. 3c) . A pathway analysis comparing MDR-TB and XDR-TB strains to susceptible strains identified only one significant annotation cluster with 17.7-fold enrichment for antibiotic resistance and response to antibiotics (P = 1.6 × 10 -7
), further confirming the robustness of the GWAS approach. Table 8 and Supplementary Data 1). The candidate genes differed in their abundance of small indels, reflecting their essentiality for survival: drug targets had a lower density of indels, whereas drug-metabolizing enzymes had a greater density. For example, the pncA gene was the most polymorphic coding region (PZA, 44.72 indels/kb), while the least polymorphic was rpoB (RIF, 2.3 indels/kb). Although most small indels (83%) in the candidate regions were 1 bp in length and caused frameshifts, the indels in rpoB inserted or deleted whole codons; that is, they did not cause a shift in the codon reading frame. Indels in rpoB, pncA and the embAB promoter region were associated with MDR-TB, XDR-TB and their respective targets/activators. Indels in ethA were associated with ETH resistance and XDR-TB. Similarly, gid indels were associated with STM, as expected.
Association tests using small indels and large deletions. An analysis of genome-wide small indels revealed associations in candidate resistance genes and operons (Supplementary
The analysis of CYS revealed indel associations with the ald gene, supporting recent reports that loss of function in ald confers resistance 11 . Thus, resistance to CYS appears to be conferred by both SNPs in alr and indels in ald. Indels found in rrs were associated with KAN and CAP resistance; however, they did not reach statistical significance for STM, which has a different drug-binding site. CAP resistance was also found to be associated with three indels in tlyA, two of which are located at the 3′ end of the gene. In general, indels were distributed throughout the gene lengths; however, there was some evidence of areas of higher density, such as the pncA region between codons 130 and 132 (close to the catalytic center) and the codon 427-434 region in rpoB.
The only large deletion association identified by GWAS was an association between a region encompassing the thyA and dfrA genes and PAS resistance. Five samples across four countries contained large thyA-dfrA deletions of varying length ( Supplementary Fig. 4 and Supplementary Table 9 ). Associations of partial or whole-gene deletions in katG, ethA and pncA were close to statistical significance (P < 0.05). These genes activate prodrugs, and none are considered to be essential to Mtb survival. The large deletions detected occurred independently in different branches of the phylogenetic tree and are likely to offer an alternative route to resistance as compared to small genomic variants, across lineages and populations.
Effects on resistance prediction using GWAS variants. We sought to establish whether any of the mutations found in association and homoplastic analyses increased the predictability of resistance phenotypes for individual drugs (Table 3) . We used the reported phenotypic drug susceptibility test result as the reference standard to calculate the sensitivity and specificity for mutation resistance predictions. Using a previously established library of mutations 8, 17 (TBDR library), we found that, although the sensitivity was greater than 80% for 8 of 14 drugs, a substantial proportion of resistance phenotypes were not explained by known mutations, particularly in second-line drugs. Using the novel SNPs identified in this study, we gained sensitivity for PAS (+ 10%), ETH (+ 14%) and CYS ( + 50%; not included in the TBDR library) ( Table 3 ). The additional inclusion of small indels and large deletions further improved the predictive ability for nine drugs while maintaining specificities of at least 90%, except for ETH, which was 72% (Table 3) .
Discussion
To provide genomic insights into Mtb drug resistance, we have combined the power of whole-genome sequencing with a genomewide association analytical approach in the largest and most geographically widespread study thus far, encompassing a total of 6,465 clinical isolates of Mtb from more than 30 countries. Large sample sizes are required to identify complex or infrequent genetic effects, but also to negate effects due to possible errors in phenotypic drug susceptibility testing and misclassification 43 . The lack of standardization of phenotypic testing methodologies for Mtb is also a potential source of bias, which was reduced by the inclusion of samples from different countries and laboratories using a variety of qualityassured testing methodologies. While resistant phenotypes may be imputed from established resistance-causing mutations, susceptibility to a drug cannot be assumed in the absence of corroborating evidence 17 . The completeness of our susceptibility test data meant that both GWAS and homoplasy-based methods could be applied across 14 drugs.
The GWAS identified well-established resistance-conferring loci and compensatory relationships, thereby confirming the authenticity and robustness of the approach. It also identified several recently discovered loci (folC, ubiA, thyX-hsdS.1, thyA, alr, ald and dfrA-thyA), new epistatic relationships (pncA with pncB2 and thyA with thyX-hsdS.1), and efflux pumps represented by the ABC transporters drrA and Rv2688c associated with drug resistance. The novel genetic markers associated with resistance identified in this GWAS included SNPs in the ethA and thyX promoters, small indels in pncA and ald, and large deletions in prodrug activators such as ethA and katG. These loci warrant functional follow-up and characterization studies to fully elucidate their role in treatment failure. The associations identified may shed light on the molecular mechanisms underlying drug resistance and assist in the design of novel antibiotics.
In our study, sample sizes for second-line drugs were reduced in comparison to those for first-line drugs. This was due to the lower prevalence of resistance to second-line drugs and the fact that isolates susceptible to first-line drugs are not routinely tested for sensitivity to second-line drugs. However, because of the large effect that causal mutations have on drug resistance phenotypes, relatively small samples of bacterial genomes can be sufficient to identify causal mutations 43 , as has been demonstrated in previous studies on Mtb [10] [11] [12] . It should be noted that bedaquiline, delamanid and linezolid were excluded from our analysis owing to the paucity of phenotypic susceptibility data.
The analysis highlighted the importance of indels to drug resistance, particularly their high density in drug-metabolizing genes, in contrast to highly essential drug target genes, where their density was low. The inclusion of small indels and large deletions improved the predictability of resistance phenotypes. However, for drugs like CYS and PAS, mechanisms of drug resistance remain unknown, and larger numbers of resistant cases will be required to elucidate them. It is also possible that unknown mechanisms may be explained by epigenetics and gene expression 44 . Mtb strains are usually classified as drug resistant or susceptible on the basis of their capacity to grow in vitro when exposed to a critical concentration of the drug. Phenotypic testing methods have a degree of uncertainty, especially close to the threshold 43 . Testing against a range of drug concentrations to establish the MIC is a preferred approach to determine the level of resistance but is not routinely undertaken 40 . MIC values were not available for every isolate presented here, but despite this limitation loci known to be involved in low levels of resistance (Table 3) were identified by our analysis. Indeed, our analysis identified a relationship between known levels of resistance and the odds ratios from the GWAS, which could aid the clinical interpretation of molecular diagnostic data, including measuring the sensitivity and specificity of individual mutations when diagnosing drug resistance.
Emergence of resistance is driven by drug exposure, and local TB treatment practices are a major influence on the prevalence and pattern of resistance. A limitation of this study was the sampling methodology, as collection of the isolates was not controlled or systematic and resistant isolates were not evenly distributed across collection sites. However, within our study population, we covered the four major Mtb lineages across five continents and sampled multiple geographic regions, allowing us to observe differences in the prevalence of drug-resistance-conferring mutations and mechanisms. Some drug resistance and compensatory/epistatic relationships were found to vary across geographic populations and bacterial lineages, implying that regional variation should be considered to fully characterize genotype-phenotype relationships. The differential lineage effects could impact on relative virulence between strain types. Enhanced understanding of the genetic basis of phenotypic antituberculosis drug resistance will also aid in the development of more accurate molecular diagnostics for drug-resistant TB. An important finding of this study is the significance of genomic variation other than SNPs, which has implications for the design of molecular tests for resistance. Improved tools are needed to guide treatment of patients with multidrug-resistant disease, where personalized treatment offers improved rates of cure 45 . Nextgeneration sequencing offers a comprehensive assessment and may be used to guide treatment 45 . Although such technology is currently being implemented in some low-burden countries such as the UK, it remains to be trialed in resource-poor settings that are representative of most patients with TB worldwide.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41588-017-0029-0. 
Sequence data and variant calling. Sequence data for 6,465 M. tuberculosis complex clinical isolates were generated as part of a collaborative global drug resistance project (n = 2,637; http://pathogenseq.lshtm.ac.uk/) or downloaded from the public domain (n = 3,828) (Supplementary Table 1 ). All isolates had undergone drug susceptibility testing by phenotypic methods. These isolates represented multiple populations from different geographic areas and all four main lineages (1-4) (Supplementary Table 1 ). The 2,637 samples not previously sequenced were Illumina sequenced, generating paired-end reads of at least 50 bp with at least 50-fold genome coverage. The analytical workflow for the raw sequence data is summarized in Supplementary Fig. 5 . The new and archived raw sequence data were aligned to the H37Rv reference genome (Genbank accession NC_000962.3) using the BWA mem algorithm 46 (settings: --c 100 --T 50). SAMtools/BCFtools 47 (default settings) and GATK 48 software were used to call SNPs and small indels. The GATK parameters used were -T UnifiedGenotyper -ploidy 1 -glm BOTH -allowPotentiallyMisencodedQuals 2. The overlapping set of variants from the two algorithms was retained for further analysis. Alleles were additionally called across the whole genome (including SNP sites) using a coverage-based approach 5, 49 . A missing call was assigned if the total depth of coverage at a site did not reach a minimum of 20 reads or none of the four nucleotides accounted for at least 75% of the total coverage. Samples or SNP sites having an excess of 10% missing genotype calls were removed. This quality control step was implemented to remove samples with poor-quality genotype calls due to poor depth of coverage or mixed infections. The final dataset included 6,465 isolates and 102,160 genome-wide SNPs. Delly2 software 50 was used to identify large deletions. All large deletions were confirmed using localized de novo assembly, and those found in association analysis (dfrA/thyA, pncA, ethA/ethR and katG) were confirmed using PCR.
Phenotypic drug susceptibility testing. Drug susceptibility data were obtained from WHO-recognized testing protocols 51 . The Mtb isolates that provided sequence data included in this study are summarized in Supplementary Table 1 . Each sequence included in the study was derived from an isolate from an individual patient. Some DNA samples were from archived stocks (for example, India, collected before 2009 and Malawi, collected between 1996 and 2010), and others were extracted specifically for this study. Information regarding isolates with previously reported sequence data was derived from published materials. Isolates were classed as resistant or susceptible to a drug on the basis of phenotypic testing using the BACTEC 460 TB System (Becton Dickinson), the BACTEC Mycobacterial Growth Indicator Tube (MGIT) 960 system (Becton Dickinson) 52 , solid agar or Lowenstein-Jensen slopes 53, 54 . Not all samples were tested for resistance to all drugs; most notably, some isolates found susceptible to first-line drugs were not subjected to testing for resistance to second-line drugs. Where isolates were not tested for resistance to a particular drug, they were excluded from the analysis for that drug. Drug susceptibility testing was mainly undertaken in local laboratories participating in the WHO supranational laboratory network using the recognized testing protocols 51 . Isolates from Malawi were shipped to the UK's Mycobacterium Reference Laboratory for testing. Isolates from Uganda were tested at the Joint Clinical Research Centre (JCRC) in Kampala, with quality control performed by the US Centers for Disease Control and Prevention (CDC).
The Peruvian isolates were initially tested for resistance to RIF and INH using the Microscopic Observation Drug Susceptibility (MODS) assay 54 at the Universidad Peruana Cayetano Heredia (UPCH) before transfer to the national reference laboratory for further testing. In Peru, susceptibility to PZA was assessed by the Wayne assay, a colorimetric biochemical test in which PZA is hydrolyzed to free pyrazinoic acid 55 . Testing using the BACTEC 960 MGIT or BACTEC 460 (Becton Dickinson) was performed according to the manufacturer's indications 56 . PZA sensitivity was determined using BACTEC 7H12 liquid medium, pH 6.0, at 100 μ g/ml (BACTEC PZA test medium, Becton Dickinson). When testing on agar, the critical drug concentrations used were as follows: RIF, 1 μ g/ml; INH, 0.2 μ g/ml; STM, 2 μ g/ml; EMB, 5 μ g/ml; CIP, 2 μ g/ml; AMK, 5 μ g/ml; CAP, 10 μ g/ml; KAN, 5 μ g/ml (Pakistan, 6 μ g/ml); ETH, 5 μ g/ml; PAS, 2 μ g/ml 53 . For Lowenstein-Jensen testing, the drug concentrations used were as follows: STM, 4.0 μ g/ml; INH, 0.2 μ g/ml; RIF, 40.0 μ g/ml; EMB, 2.0 μ g/ml; CAP, 40.0 μ g/ml; KAN, 30.0 μ g/ml (China) or 20.0 μ g/ml (Vietnam); OFL, 2.0 μ g/ml; ETH, 40 μ g/ml; thioacetone, 10 μ g/ml; PZA, 200 μ g/ml; CYS, 30 μ g/ml; PAS, 0.5 μ g/ml 55 .
Phylogenetic tree and association analysis. The best scoring maximumlikelihood phylogenetic tree rooted on M. canetti (Genbank accession HE572590) was constructed by RAxML software 57 (10,000 bootstrap samples) using the 102,160 high-quality SNP sites. Spoligotypes were inferred in silico using SpolPred 58 , and strain types were determined using lineage-specific SNPs 5 . Further population structure assessment was performed using principal-components analysis ( Supplementary Fig. 2 ), which clustered samples by genotype congruently with the phylogenetic tree. The principal components were calculated from a SNP pairwise distance matrix between each sample, and the first five components (summarizing 82.7% of genetic variation) were used as covariates in the regressionbased association models. Mixed regression models were employed to estimate the strength of association between the binary drug resistance outcome (resistant versus susceptible) and the aggregate number of mutations (SNPs, indels or large deletions) by coding regions, RNA loci and intergenic regions, as well as operons 49 . The low frequency of variants required the aggregation of mutations to increase the power of detecting associated loci, and a mixed-model approach has been demonstrated to work well at adjusting for the confounding effects of Mtb lineage, sublineage and outbreak-based population structure 49 . Operons, or functional units containing clusters of genes under the control of the same promoter, were determined from TBDB (see URLs). Gene function was extracted from the TubercuList webserver (see URLs). The mixed models also included the principal components to account for main Mtb lineage and sublineage effects and a SNP-inferred kinship matrix as a random effect to account for highly related samples and fine-scale population structure due to potential outbreaks 49 . These models were implemented in GEMMA (v.1.1.2) software 59 . A SNP-based GWAS was used to identify individual variants associated with drug resistance expected to fall within the genes found associated in the 'main' analysis. To minimize any co-resistance between drugs, we adjusted for the presence of other resistance in the regression models. Co-resistance is expected to result from exposure to multiple antituberculosis drugs and the stepwise accumulation of mutations. Statistical significance thresholds to account for multiple testing were established using a permutation approach that sorted phenotypic test data without replacement and again performed GWAS analysis (10,000 times). We report all findings that are below a calculated permutation threshold of P < 1 × 10
. All statistical analyses were performed using R software. To identify SNPs enriched for convergent evolution and provide further evolutionary evidence, the phylogenetics-based phyC approach was employed 9 using the implementation made available in a previous study 60 . Any potential co-resistance effects were dissected through consulting gene annotation and published literature to report the most plausible role in drug resistance. Additionally, long branches in the phylogenetic tree leading up to clades enriched with drug-resistant isolates result in spurious associations. Mutations truly conferring drug resistance often originate multiple times independently in the phylogeny. Mutations that originated once in the tree (clade-specific mutations), which are likely to lead to spurious associations, were removed from the GWAS results.
Detection of putative compensatory mechanisms. Loci were identified as being putative compensatory loci if they (i) were associated with drug resistance, (ii) harbored homoplastic mutations, (iii) shared a similar biological function with a known drug target or drug-activating enzyme, and (iv) were significantly more mutated in the presence of mutations in the gene encoding the drug target or drugactivating enzyme. In the fourth analysis, deep phylogenetic and synonymous SNPs were removed before calculating the number of samples with nonsynonymous SNPs at genes of interest (for example, p.Ala1075Ala at rpoB or p.Glu1092Asp at rpoC). The significance of differences between studied genes was calculated using Fisher's exact test (cutoff of P < 1 × 10
−8
).
Protein mutation modeling. Apo crystal structures for Alr were downloaded from the Protein Data Bank (PDB 1XFC 61 ) and then subjected to modeling of missing residues, WinCOOT regularization and removal of pyridoxal 5′ -phosphate from both chains. The mCSM and DUET web servers were used to assess changes in protein stability, mCSM-PPI was used to quantify effects on protein-protein interactions and mCSM-Lig was used to quantify effects on drug binding [62] [63] [64] . For ligand binding, d-cycloserine was modeled in the active site using UCSF Chimera v1.11 65 from the coordinates of the closest holohomolog Clostridium difficile 630 (PDB 4LUT) 66 .
Statistical analyses.
The statistical mixed models used for association analysis are described above. The terms 'low' , 'intermediate' and 'high' levels of resistance referred to in the text and Fig. 3 denote whether a mutation is known to confer low, intermediate or high MIC values, respectively, as reported in the literature 18, 40, [67] [68] [69] [70] [71] . Wilcoxon tests and linear regression models were used to compare differences in log odds ratios between resistance levels. Samples that had more than one known resistance-causing variant were removed from these calculations. R statistical software (v3.4.1; see URLs) was used to perform this analysis. The R library maps was used to generate the world map with lineage and drug resistance frequencies. 
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